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DSB = double-strand break; NHEJ = nonhomologous end joining.
Available online http://breast-cancer-research.com/content/4/1/009
Introduction
Almost 5% of individuals with breast cancers are predis-
posed to the disease by genetic mutations. The discovery
of the BRCA1 and BRCA2 genes, and of how mutations
in these genes lead to the onset of breast and ovarian
cancers has provided new insights into the molecular
mechanisms that lead to tumourigenesis and have
improved our understanding of cancer predisposition
[1–3]. In current research the roles of BRCA1 and
BRCA2 are beginning to be unravelled, and it is hoped
that identification of the precise properties of BRCA1 and
BRCA2 will provide an important key to cancer prevention
and development of new cancer treatments.
Both BRCA1 and BRCA2 are essential genes for cellular
development; deletions in either gene lead to embryonic
lethality in mice [4–8]. Genetic studies conducted in
BRCA1- and BRCA2-defective cell lines [7,9,10] have
further revealed that these tumour suppressor genes are
required for maintenance of genome integrity and for
normal levels of resistance to DNA damage. Moreover,
without functional BRCA genes, cells are inefficient in
repairing DNA damage by homologous recombination
[11–14], which can lead to apoptosis or cell transforma-
tion [15,16].
Early studies on BRCA1 (208 kDa) and BRCA2 (384
kDa) led to the conclusion that the two proteins function
together as part of a complex that acts directly in double-
strand break (DSB) repair. First, BRCA1- and BRCA2-
defective cell lines and knockout mice exhibit similar
sensitivities to DNA-damaging agents [4,16]. Second,
BRCA1- and BRCA2-defective cell lines show defects in
DSB repair by homologous recombination [12,14]. Third,
the BRCA1 and BRCA2 proteins co-localize to DNA-
damage-induced nuclear foci, and to foci that appear in S
phase [17]. Even though BRCA1 and BRCA2 are able to
interact with each other, however, only a minority of the
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BRCA1 was actually found in association with BRCA2
[17,18]. Moreover, the recent identification of proteins that
associate with either BRCA1 or BRCA2 indicates that the
two BRCA proteins each participate in different protein
complexes, and that these complexes may play quite dis-
tinct roles in DSB repair.
A summary of some of the interactions that have been
described for BRCA1 is shown in Fig. 1. In brief, BRCA1
has been shown to be part of a genome surveillance
complex termed BASC, which contains a number of pro-
teins that are important for efficient DNA repair (the
MRE11/RAD50/NBS1 repair complex, proteins involved
in mismatch repair such as the MSH2/MSH6 and PMS2/
MLH1 heterodimers, the DNA-damage-signalling protein
kinase ATM, BLM helicase and replication factor-C) [18].
Additionally, BRCA1 associates with RNA polymerase II
holoenzyme, the cell-cycle-checkpoint kinase ATR, a
SWI/SNF chromatin-remodelling complex, the Fanconi’s
anaemia protein FANCD2, and a number of other impor-
tant proteins (for review [19,20]). In many cases, however,
the specificity and significance of these protein/protein
interactions may require further investigation. The interac-
tions of BRCA2 appear more limited, with the most illumi-
nating interaction being that of BRCA2 with the essential
homologous recombination/repair protein RAD51 [21].
In the present commentary we focus our attention on a
putative DNA helicase termed BACH1, which was
recently shown to interact with BRCA1, and on another
BRCA1-interacting protein known as BARD1 [22–24]. By
comparing various aspects of the BRCA1/BARD1/
BACH1 complex and the BRCA2/RAD51 complex, we
attempt to account for the related repair-defective pheno-
types associated with BRCA1 and BRCA2 mutations.
Regulation of BACH1 functions in DNA repair
by BRCA1
The carboxyl-terminal region of BRCA1 contains two
BRCT motifs, which are important for protein/protein inter-
actions [25]. Interestingly, many cancer-associated muta-
tions in BRCA1 result in the formation of a truncated
BRCA1 protein, in which the carboxyl-terminal region has
been deleted. It is therefore possible that proteins that
interact with the BRCT motifs of BRCA1 may play impor-
tant roles in BRCA1-dependent tumour suppression.
Recently, Cantor et al. [24] identified a novel 130-kDa
polypeptide on the basis of its interaction with the BRCT
motifs of BRCA1. Analysis of the sequence revealed that
the protein contained the seven motifs that are character-
istic of the DEAH helicase family, leading to the name
BACH1 (BRCA1-associated carboxyl-terminal helicase).
However, intrinsic DNA helicase activity has not yet been
demonstrated. The association of BRCA1 with BACH1
was confirmed by three independent methods:
GST–BRCA1 fusion proteins were used to affinity purify
BACH1 from whole-cell extracts; BRCA1 and BACH1
were co-immunoprecipitated from MCF-7 cells using
either anti-BRCT antibodies or anti-BACH1 antibodies;
and BRCA1 and BACH1 were shown to co-localize to
nuclear foci in S and G2 phase cells by immunofluores-
cence microscopy. Most importantly, functional BRCA1
was shown to be essential for nuclear focus formation by
BACH1, suggesting that BRCA1 plays a role in regulating
the cellular localization of BACH1.
BRCA1 is potentially involved in transcription, replication
and DNA repair, and it is therefore possible that the puta-
tive helicase BACH1 could be involved in any of these cel-
lular processes. In order to address the significance of
BACH1 in DSB repair, Cantor et al. [24] showed that
over-expression of a BACH1 gene carrying a mutation in
Figure 1
Interactions of BRCA1 and BRCA2 with other proteins, or protein
complexes. as determined by two-hybrid screens, co-immunoprecipitation
analyses and co-fractionation studies. In general, the protein–protein
associations of BRCA1 have been shown to be distinct from those
exhibited by BRCA2.c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
r
e
s
e
a
r
c
h
 
a
r
t
i
c
l
e
the sequence encoding the conserved lysine residue
(Lys52→Arg) in the ATPase domain greatly decreased the
ability of the cells to repair DSBs promptly [24]. Interest-
ingly, this dominant-negative phenotype was rescued by
over-expression of BACH1 carrying a second mutation
that abolished interactions between the mutant BACH1
and BRCA1. Those findings show that the repair function
of BACH1 is mediated through its interactions with
BRCA1. It is possible that BRCA1 is required for the spe-
cific recruitment of BACH1 to the sites of repair.
BACH1 mutations have been identified in two out of 65
women with early-onset breast cancer [24], one of whom
had a familial history of breast and ovarian cancer. Both
individuals were normal for BRCA1 and BRCA2. One
mutation (Pro47→Ala), in the highly conserved ATP-
binding domain, was found to lead to destabilization of
BACH1 protein. Clearly, this mutation will result in loss of
function of BACH1. The second mutation (Met299→Ile) is
a conservative substitution in a nonconserved residue, and
its functional significance is unclear. Unfortunately, the
correlation of these mutations with DSB repair efficiency
and genomic instability was not determined.
Additional functions of BRCA1 in DNA repair
indicated by interactions with BARD1
Another protein that is known to interact with the
BRCA1/BACH1 complex is BARD1 [24]. First isolated in
a two-hybrid screen for BRCA1-interacting proteins, both
BARD1 and BRCA1 contain a conserved RING finger
motif, which is often linked to either DNA binding or ubiq-
uitination [22]. The RING finger motif of BRCA1 has been
shown to possess ubiquitin ligase activity, which is greatly
stimulated by binding to BARD1 [23,26]. Significantly, a
breast-cancer-associated  BRCA1 mutation within the
RING finger motif abolished the ubiquitin ligase activity of
BRCA1, indicating that this activity is important for the
action of BRCA1 in tumour suppression [26]. Moreover,
several mutations located in the RING finger motif of
BRCA1, which disrupt the ubiquitin ligase activity, have
also been shown to cause increased sensitivity to DNA-
damaging agents. This correlation suggests an additional
role for BRCA1 in repair of DNA damage, in addition to its
role as a regulator for BACH1, in targeting protein(s) for
degradation.
Interestingly, BRCA1 also interacts with BAP1, a ubiquitin
hydrolase [27]. Because BAP1 and BARD1 can modulate
ubiquitination by BRCA1, and both bind the RING motif of
BRCA1, there appears to be an intriguing interplay between
these proteins in terms of the promotion (BARD1) or pre-
vention (BAP1) of ubiquitin-mediated protein degradation.
A likely target for the ubiquitin ligase activity of BRCA1 is
the Fanconi anaemia protein FANCD2, which is known to
be mono-ubiquitinated in a BRCA1-dependent manner in
response to DNA damage [28]. Consistent with this pro-
posal, FANCD2 co-localizes with BRCA1 in DNA-
damage-induced nuclear foci, FANCD2 and BRCA1 can
be co-immunoprecipitated together, and mutations in
FANCD2 result in hypersensitivity to various DNA-damag-
ing agents [28].
Distinct roles for BRCA1/BACH1 and
BRCA2/RAD51 complexes in repair of
double-strand breaks
Because BRCA1 interacts with a wide range of proteins, it
is likely that the protein plays a multifunctional role in DNA
metabolism. Two such roles may be defined by its interac-
tions with BACH1 and with BARD1, both of which impact
on the efficiency of DNA repair (Fig. 2). These functions
may also require phosphorylation of BRCA1 by the protein
kinase ATM in response to DNA damage [7]. What, then,
are the precise functions of the BRCA1/BACH1/BARD1
complex in relation to recombinational repair? It is interest-
ing that several of the proteins that interact with BRCA1
exhibit helicase/nuclease activities (e.g. the BACH1, BLM,
MRE11/RAD50/NBS1 complex) and it is possible that
BRCA1 may assist the targeting of these proteins to
DSBs, where they play a role in break resection. Alterna-
tively, proteins that interact with BRCA1 may be involved
in the processing of recombination intermediates that
contain Holliday junctions. Support for these potential
roles comes from observations indicating that BRCA1
binds DNA and inhibits the exonuclease activities of the
MRE11/RAD50/NBS1 complex, and that it also displays a
preference for branched DNA structures [29]. The ubiqui-
tin ligase activity of the BRCA1/BACH1/BARD1 complex
might be important for down-regulating proteins that are
involved in cell/cycle progression during the initial step of
DNA repair, or DNA recombination proteins after the
repair process is completed.
Like cells that are defective in BRCA1, BRCA2-defective
cells are also defective in homologous recombination [14],
leading to the repair of DSBs by alternative mechanisms
that involve nonhomologous end joining (NHEJ) [9,30].
The consequences of NHEJ can be disastrous for the cell
because, unlike the conservative process of homologous
recombination, NHEJ can occur between breaks on differ-
ent chromosomes, resulting in chromosomal transloca-
tions or deletions. Such changes can lead to improper
regulation of gene expression that could, in turn, result in
cell transformation and cancer development.
BRCA2 protein interacts directly with the RAD51 protein,
the cellular recombinase that is essential for the initiation
of DNA/DNA interactions that lead to strand exchange
[31]. The ease with which these two proteins can be co-
immunoprecipitated from cell-free extracts [17] indicates
that BRCA2 may play a more direct role in DNA repair
than BRCA1 (Fig. 2). RAD51 interacts with BRCA2 by
Available online http://breast-cancer-research.com/content/4/1/009binding to a series of BRC repeats that are present in
BRCA2 [21,32]. In recent in vitro studies [33], it was
shown that peptides that correspond to the BRC3 or
BRC4 repeats of BRCA2 bind RAD51 and block its ability
to form nucleoprotein filaments on DNA. This observation
helps to explain the results of earlier studies conducted by
Chen et al. [34], in which it was shown that over-expres-
sion of the BRC4 repeat in mammalian cells resulted in a
hypersensitivity to DNA-damaging agents. Presumably,
high levels of the BRC4 repeat competed with BRCA2 for
RAD51, resulting in a dominant-negative phenotype.
Because DNA binding and nucleoprotein filament forma-
tion by RAD51 is required for all recombination activities
exhibited by the protein, those observations indicate that
BRCA2 plays an important regulatory role with respect to
RAD51. Those studies also showed that mutations within
the BRC region that mimic cancer-associated BRCA2
mutations failed to inhibit DNA binding by RAD51.
As part of the cellular response to DNA damage, RAD51
and BRCA2 co-localize to damage-induced foci, which
are believed to represent sites where DSB repair takes
place [17,35]. Therefore, it is possible that the RAD51/
BRCA2 interaction prevents the constitutive binding of
RAD51 to undamaged DNA, and that the RAD51 bound
by BRCA2 will be reserved for immediate localization to
sites of DNA damage. If this is the case, then there has to
be a change in the RAD51/BRCA2 interaction in
response to DNA damage that allows RAD51 to bind
DNA and initiate the formation of nucleoprotein filaments
at the sites of DSBs. Such a change might involve DNA-
damage-induced phosphorylation of either BRCA2 or
RAD51. Mutations that affect the ability of BRCA2 to
interact with RAD51, or cause defects in the relocalization
of the BRCA2/RAD51 complex, would be expected to
have severe effects on the normal efficiency of homolo-
gous recombination, potentially leading to gross chromo-
somal rearrangements and cell death.
Although RAD51 co-localizes with both BRCA1 and
BRCA2 in S-phase nuclei and in cells treated with DNA-
damaging agents, it is important to bear in mind that the
majority of BRCA1 does not physically associate with
BRCA2 and RAD51 [17,18]. Similarly, there appears to be
a pool of RAD51 that fails to form complexes with BRCA2.
Indeed, to our knowledge, a ‘protein complex’ that contains
BRCA1, BRCA2 and RAD51 has yet to be isolated. More-
over, it should be emphasized that most of the proteins that
have been shown to interact with BRCA1 fail to associate
with BRCA2, and vice versa (Fig. 1). Such exclusivity sup-
ports the argument that these two tumour suppressors
form distinct complexes in vivo, although it is also likely that
these complexes may interact in terms of their repair func-
tions. The co-localization of these proteins in nuclear foci
only suggests that these two complexes are localized to
potential repair sites; it does not necessarily mean that the
three proteins interact directly and act in concert.
Conclusion
In summary, we suggest that BRCA1 and BRCA2 are
capable of playing quite different roles, although it is
undoubtedly also possible that complexes containing
BRCA1 and BRCA2 may interact transiently to effect key
reactions in DSB repair. It is hoped that further dissection
of the functions of the novel partner proteins, present in
complexes either with BRCA1 or BRCA2, will help to
define the precise roles of BRCA1 and BRCA2 in DSB
repair. Until then, the proposal that these important pro-
teins influence the same or different steps of the DSB
repair pathway will remain open to discussion and insight-
ful experimentation.
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